Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation
These analyses identify the likely ceiling price and various initial price offer scenarios for the second round of Medicare price negotiation. We report price benchmarks and likely therapeutic alternatives to improve transparency around the opaque CMS negotiation process.
Authors
- Sean D. Sullivan (ORCID: https://orcid.org/0000-0003-3052-6540)
- Nico Gabriel (ORCID: https://orcid.org/0000-0003-1793-2245)
- Kevin H. Li
- Emma M. Cousin (ORCID: https://orcid.org/0000-0003-1208-2173)
- Kristi Martin
Institutions
- University of Washington (US)
- University of California San Diego (US)
- Camber Collective (United States) (US)
- University of Montana (US)
- London School of Economics and Political Science (GB)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-09-12
- DOI
- https://doi.org/10.18553/jmcp.2025.25199
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 3.13